Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma
Metrics: PDF 1880 views | HTML 2102 views | ?
Huiting Su1,*, Bing Li1,*, Lan Zheng1, Haixia Wang1, Liping Zhang1
1Department of Laboratory Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China
*These authors have contributed equally to this work
Liping Zhang, email: [email protected]
Keywords: cytoplasmic transduction peptide, FoxM1, dendritic cells, hepatocellular carcinoma, immunotherapy
Received: November 05, 2015 Accepted: June 09, 2016 Published: June 24, 2016
Application of dendritic cells (DCs) pulsed with tumor-associated antigens is considered attractive in immunotherapy for hepatocellular carcinoma (HCC). In order to efficiently prime tumor-associated antigens specific for cytotoxic T lymphocytes (CTLs), it is important that DCs present tumor-associated antigens on MHC class I. MHC class I generally present endogenous antigens expressed in the cytosol. In this study, we developed a new antigen delivery tool based on cross presentation of exogenous antigens in DCs by using cytoplasmic transduction peptide (CTP). CTP protein could transduce FoxM1 tumor antigen into the cytosol of DCs, and CTP-FoxM1 fusion protein could stimulate activation and maturation of DCs. DCs pulsed with CTP-FoxM1 could induce specific CTLs. More importantly, the immunity induced by DCs loaded with CTP-FoxM1 could significantly inhibit tumor growth and metastasis in HCC-bearing mice, which was more potent than that induced by DCs loaded with FoxM1 or CTP, alone. Our results indicate that DCs pulsed with CTP-FoxM1 might be a promising vaccine candidate for HCC therapy and provide new insight into the design of DC-based immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.